The growing prevalence of nonalcoholic fatty liver disease (NAFLD), determined by fatty liver index, amongst young adults in the United States. A 20-year experience

Abstract

Aim: The Global burden of nonalcoholic fatty liver disease (NAFLD) has significantly increased recently, with its prevalence mirroring increasing obesity and diabetes. However, population-specific evidence for young adults remains limited. Herein, we provide a 20-year trend analysis of NAFLD in young adults and examine factors associated with NAFLD and major adverse cardiovascular events (MACE) prevalence.

Methods: This study uses data from the United States National Health and Nutrition Examination Survey (NHANES) 1999-2018. Fatty liver was examined with the fatty liver index (FLI) and United States-FLI (US-FLI), and advanced fibrosis was examined with the fibrosis-4 index. Clustered multivariate logistic regression analysis on the year of study was applied to obtain odds ratios (OR) for the estimation of events.

Results: 13.31% (95%CI: 12.71% to 13.94%) of young adults had NAFLD. The prevalence increased from 9.98% in 1999 to 19.49% in 2018, with a statistically significant trend (P < 0.001). 9.52% and 5.29% of patients have clinically significant and advanced fibrosis, respectively. In multivariate analysis, diabetes (3.48, 95%CI: 2.37 to 5.11), hypertension (2.03, 95%CI: 1.62 to 2.55), elevated body mass index (1.22, 95%CI: 1.20 to 1.23, P < 0.001) significantly increases odds of NAFLD. The largest increase in odds was related to obesity (OR: 21.61, 95%CI: 16.95 to 27.55, P < 0.001). Young adults with NAFLD had a borderline non-significant increase in the prevalence of MACE compared to individuals without NAFLD (OR: 1.603, 95%CI: 0.949 to 2.708, P = 0.078).

Conclusion: The rising prevalence of NAFLD in young adults depicts the changing landscape of NAFLD and its association with a significant increase in MACE. The challenge of effective risk stratification and education of these individuals remains.

Keywords

NAFLD / prevalence / young Adults / epidemiology

References

[1] Paik JM,Eberly KE,Henry L.Global burden of NAFLD and chronic liver disease among adolescents and young adults.Hepatology2022;75:1204-17

[2] Sanyal AJ.Past, present and future perspectives in nonalcoholic fatty liver disease.Nat Rev Gastroenterol Hepatol2019;16:377-86

[3] Lim GEH,Ng CH.An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs. NAFLD.Clin Gastroenterol Hepatol2021;11:S1542-3565(21)01276

[4] Le MH,Li X.2019 global NAFLD prevalence: a systematic review and meta-analysis.Clin Gastroenterol Hepatol2021:S1542-3565(21)01280

[5] Muthiah MD,Sanyal AJ.A clinical overview of non-alcoholic fatty liver disease: a guide to diagnosis, the clinical features, and complications-What the non-specialist needs to know.Diabetes Obes Metab2022;24 Suppl 2:3-14

[6] Targher G,Tilg H.NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications.Gut2020;69:1691-705

[7] Chew NWS,Muthiah MD.Comprehensive review and updates on holistic approach towards non-alcoholic fatty liver disease management with cardiovascular disease.Curr Atheroscler Rep2022;24:515-32

[8] Ng CH,Chin YH.The effect of diabetes and prediabetes on the prevalence, complications and mortality in non-alcoholic fatty liver disease.Clin Mol Hepatol2022;28:565-74 PMCID:PMC9293620

[9] Stefan N.A global view of the interplay between non-alcoholic fatty liver disease and diabetes.Lancet Diabetes Endocrinol2022;10:284-96

[10] Francque SM,Kwanten WJ.Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications.J Hepatol2016;65:425-43

[11] Ekstedt M,Nasr P.Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.Hepatology2015;61:1547-54

[12] Angulo P,Dam-Larsen S.Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.Gastroenterology2015;149:389-97.e10 PMCID:PMC4516664

[13] Younossi ZM,de Avila L.The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis.J Hepatol2019;71:793-801

[14] Mrad RA,Mubarak G,Zein NN.The increasing burden of nonalcoholic fatty liver disease among young adults in the United States: a growing epidemic.Hepatology2016;64:1386-7

[15] Lawlor DA,Macdonald-Wallis C.Nonalcoholic fatty liver disease, liver fibrosis, and cardiometabolic risk factors in adolescence: a cross-sectional study of 1874 general population adolescents.J Clin Endocrinol Metab2014;99:E410-7 PMCID:PMC3955251

[16] Abeysekera KWM,Hammerton G.Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study.Lancet Gastroenterol Hepatol2020;5:295-305 PMCID:PMC7026693

[17] Angi A.Obesity and diabetes: a sword of damocles for future generations.Biomedicines2020;8:478. PMCID:PMC7694547

[18] National Health and Nutrition Examination Survey (NHANES) MEC Laboratory Procedures Manual. Centers for disease control and prevention; 2017. Available from: https://wwwn.cdc.gov/nchs/data/nhanes/2017-2018/manuals/2017_MEC_Laboratory_Procedures_Manual.pdf [Last accessed on 28 Oct 2022]

[19] Ando Y.Nonalcoholic fatty liver disease and recent guideline updates.Clin Liver Dis (Hoboken)2021;17:23-8 PMCID:PMC7849298

[20] Ruhl CE.Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey.Aliment Pharmacol Ther2015;41:65-76

[21] Bedogni G,Miglioli L.The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population.BMC Gastroenterol2006;6:33 PMCID:PMC1636651

[22] Ng CH,Chew NWS.Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality.Front Cardiovasc Med2022;9:942753 PMCID:PMC9393330

[23] Alberti KG,Grundy SM.Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.Circulation2009;120:1640-5

[24] Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies.Lancet2004;363:157-63

[25] Punthakee Z,Katz P.Diabetes Canada Clinical Practice Guidelines Expert CommitteeDefinition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome.Can J Diabetes2018;42 Suppl 1:S10-5

[26] Whelton PK,Aronow WS.2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the american college of cardiology/american heart association task force on clinical practice guidelines.Hypertension2018;71:e13-e115

[27] Bosco E,McConeghy KW,Saade E.Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review.BMC Med Res Methodol2021;21:241 PMCID:PMC8571870

[28] Blanco-Grau A,Rodriguez-Algarra F.Assessing liver fibrosis using the FIB4 index in the community setting.Diagnostics (Basel)2021;11:2236 PMCID:PMC8700445

[29] Mózes FE,Selvaraj EA.LITMUS InvestigatorsDiagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.Gut2022;71:1006-19 PMCID:PMC8995830

[30] Caussy C,Nguyen P.Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.Hepatology2018;67:1348-59 PMCID:PMC5867216

[31] Ziol M,Kettaneh A.Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C.Hepatology2005;41:48-54

[32] Campos-Murguía A,González-Regueiro JA.Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease.World J Gastroenterol2020;26:5919-43 PMCID:PMC7584064

[33] Simon TG,Khalili H,Ludvigsson JF.Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.Gut2021;70:1375-82 PMCID:PMC8185553

[34] Arshad T,Biswas R,Henry L.Nonalcoholic fatty liver disease prevalence trends among adolescents and young adults in the United States, 2007-2016.Hepatol Commun2021;5:1676-88 PMCID:PMC8485885

[35] Tsatsoulis A.Metabolically healthy obesity: criteria, epidemiology, controversies, and consequences.Curr Obes Rep2020;9:109-20

[36] Chang Y,Cho J.Metabolically healthy obesity and the development of nonalcoholic fatty liver disease.Am J Gastroenterol2016;111:1133-40

[37] Vusirikala A,Bhala N,Thomas GN.Impact of obesity and metabolic health status in the development of non-alcoholic fatty liver disease (NAFLD): a United Kingdom population-based cohort study using the health improvement network (THIN).BMC Endocr Disord2020;20:96 PMCID:PMC7325099

[38] Yki-järvinen H.Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.Lancet Diabetes Endocrinol2014;2:901-10

[39] Lonardo A,Ballestri S.Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps.Hepatology2019;70:1457-69 PMCID:PMC6766425

[40] Shen H,Tayarachakul S.Association between serum cotinine level and prevalence of non-alcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey.J Investig Med2017;65:43-8 PMCID:PMC5495193

[41] Liu Y,Bi Y.Active smoking, passive smoking, and risk of nonalcoholic fatty liver disease (NAFLD): a population-based study in China.J Epidemiol2013;23:115-21 PMCID:PMC3700247

[42] Caballería L,Auladell MA.Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain.Eur J Gastroenterol Hepatol2010;22:24-32

[43] Giammarino AM,Bulsara K.Community socioeconomic deprivation predicts nonalcoholic steatohepatitis.Hepatol Commun2022;6:550-60 PMCID:PMC8870017

[44] Golovaty I,Price JC,Seligman H.Food insecurity may be an independent risk factor associated with nonalcoholic fatty liver disease among low-income adults in the United States.J Nutr2020;150:91-8 PMCID:PMC6946902

[45] Rich NE,Kanwal F.Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA.Lancet Gastroenterol Hepatol2021;6:422-4

[46] Simon TG,Hartjes K.Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality.J Hepatol2021;75:1034-41 PMCID:PMC8530955

[47] Berry JD,Garside DB.Framingham risk score and prediction of coronary heart disease death in young men.Am Heart J2007;154:80-6 PMCID:PMC2279177

[48] McPherson S,Dufour JF.Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis.Am J Gastroenterol2017;112:740-51 PMCID:PMC5418560